These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

318 related articles for article (PubMed ID: 25459178)

  • 1. Chronic myeloid leukemia-transplantation in the tyrosine kinase era.
    Innes AJ; Apperley JF
    Hematol Oncol Clin North Am; 2014 Dec; 28(6):1037-53. PubMed ID: 25459178
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Allogeneic hematopoietic stem cell transplantation for the treatment of chronic myeloid leukemia in the era of tyrosine kinase inhibitors.
    Xu LP; Huang XJ
    Chin Med J (Engl); 2013 Feb; 126(4):768-74. PubMed ID: 23422204
    [No Abstract]   [Full Text] [Related]  

  • 3. Allogeneic Transplantation in Chronic Myeloid Leukemia and the Effect of Tyrosine Kinase Inhibitors on Survival: A Quasi-Experimental Study.
    Özen M; Üstün C; Öztürk B; Topçuoğlu P; Arat M; Gündüz M; Atilla E; Bolat G; Arslan Ö; Demirer T; Akan H; İlhan O; Beksaç M; Gürman G; Özcan M
    Turk J Haematol; 2017 Mar; 34(1):16-26. PubMed ID: 27094579
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transplant to treatment-free remission: the evolving view of 'cure' in chronic myeloid leukemia.
    Yong AS; Brissot E; Rubinstein S; Savani BN; Mohty M
    Expert Rev Hematol; 2015 Dec; 8(6):785-97. PubMed ID: 26364871
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stem cell transplant for chronic myeloid leukemia in the imatinib era.
    Radich J
    Semin Hematol; 2010 Oct; 47(4):354-61. PubMed ID: 20875552
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Outcomes of imatinib and allogeneic hematopoietic stem cell transplantation in the treatment of chronic myeloid leukemia].
    Zhou M; Sha X; Qiu H; He G; Xu Y; Cen J; Pan J; Chen S; Sun A; Zhang R; Wu D
    Zhonghua Xue Ye Xue Za Zhi; 2014 Feb; 35(2):126-8. PubMed ID: 24606653
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Allogeneic Hematopoietic Stem Cell Transplantation Is an Effective Salvage Therapy for Patients with Chronic Myeloid Leukemia Presenting with Advanced Disease or Failing Treatment with Tyrosine Kinase Inhibitors.
    Nair AP; Barnett MJ; Broady RC; Hogge DE; Song KW; Toze CL; Nantel SH; Power MM; Sutherland HJ; Nevill TJ; Abou Mourad Y; Narayanan S; Gerrie AS; Forrest DL
    Biol Blood Marrow Transplant; 2015 Aug; 21(8):1437-44. PubMed ID: 25865648
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Who with chronic myelogenous leukemia to transplant in the era of tyrosine kinase inhibitors?
    Maziarz RT
    Curr Opin Hematol; 2008 Mar; 15(2):127-33. PubMed ID: 18300759
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Response to tyrosine kinase inhibitor therapy in patients with chronic myelogenous leukemia relapsing in chronic and advanced phase following allogeneic hematopoietic stem cell transplantation.
    Wright MP; Shepherd JD; Barnett MJ; Nantel SH; Sutherland HJ; Toze CL; Hogge DE; Nevill TJ; Song KW; Abou Mourad YR; Narayanan S; Power MM; Smith CA; Forrest DL
    Biol Blood Marrow Transplant; 2010 May; 16(5):639-46. PubMed ID: 20005967
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A comparison of donor lymphocyte infusions or imatinib mesylate for patients with chronic myelogenous leukemia who have relapsed after allogeneic stem cell transplantation.
    Weisser M; Tischer J; Schnittger S; Schoch C; Ledderose G; Kolb HJ
    Haematologica; 2006 May; 91(5):663-6. PubMed ID: 16627251
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current role of stem cell transplantation in chronic myeloid leukaemia.
    Gratwohl A; Heim D
    Best Pract Res Clin Haematol; 2009 Sep; 22(3):431-43. PubMed ID: 19959092
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [An advance in the treatment of CML].
    Ohnishi K
    Gan To Kagaku Ryoho; 2007 Dec; 34(13):2185-90. PubMed ID: 18079618
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of allogeneic transplantation in chronic myeloid leukemia.
    Heim D; Gratwohl A
    Expert Rev Hematol; 2008 Oct; 1(1):41-50. PubMed ID: 21083006
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment strategies for CML.
    Goldman JM
    Best Pract Res Clin Haematol; 2009 Sep; 22(3):303-13. PubMed ID: 19959082
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Second-generation tyrosine kinase inhibitors before allogeneic stem cell transplantation in patients with chronic myeloid leukemia resistant to imatinib.
    Breccia M; Palandri F; Iori AP; Colaci E; Latagliata R; Castagnetti F; Torelli GF; Usai S; Valle V; Martinelli G; Rosti G; Foà R; Baccarani M; Alimena G
    Leuk Res; 2010 Feb; 34(2):143-7. PubMed ID: 19481800
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular monitoring to improve outcomes in patients with chronic myeloid leukemia in chronic phase: importance of achieving treatment-free remission.
    Erba HP
    Am J Hematol; 2015 Mar; 90(3):242-9. PubMed ID: 25410137
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Outcomes Following Bone Marrow Transplantation in Children With Accelerated Phase or Blast Crisis Chronic Myelogenous Leukemia in the Era of Tyrosine Kinase Inhibitors.
    Shulman DS; Lee MA; Lehmann LE; Margossian SP
    J Pediatr Hematol Oncol; 2016 Nov; 38(8):610-614. PubMed ID: 27403776
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Maintenance therapy with tyrosine kinase inhibitors after transplant in patients with chronic myeloid leukemia.
    Bar M; Radich J
    J Natl Compr Canc Netw; 2013 Mar; 11(3):308-15. PubMed ID: 23486457
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early allogeneic stem cell transplantation for chronic myelogenous leukemia in the imatinib era: a preliminary assessment.
    Simon W; Segel GB; Lichtman MA
    Blood Cells Mol Dis; 2006; 37(2):116-24; discussion 125-7. PubMed ID: 16904348
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hematopoietic cell transplantation for chronic myeloid leukemia in developing countries: perspectives from Latin America in the post-tyrosine kinase inhibitor era.
    Pasquini MC
    Hematology; 2012 Apr; 17 Suppl 1():S79-82. PubMed ID: 22507787
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.